CEO Vas Narasimhan has said Novartis' Advair generic—specifically its approval this year—was one of his top three worries. That worry just grew.

Amid a Street-beating Q4 report, GlaxoSmithKline quantified the hit it’s been bracing for: Advair generics. Short answer? Half its U.S. sales.

Thanks to new competition from AbbVie, Gilead's important hep C franchise will have another rough year in 2018.

Pfizer, Astellas and J&J envision a wide-open field for patients whose prostate cancer hasn't spread. But there's a high-stakes market scrum…

Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018…

Incoming Novartis chief Vas Narasimhan outlined his big goals as CEO on Wednesday: Think drug launches and more drug launches.

AstraZeneca and Merck's first-in-class ovarian cancer drug Lynparza just won a coveted approval to treat BRCA-mutated breast cancer.

The 2018 J.P. Morgan Healthcare Conference is receding in biopharma's rearview mirror, but industry watchers have only begun digesting the commentary.

With PCSK9 cholesterol drug Praluent ramping up more slowly than expected, Sanofi and Regeneron plan a new investment in blockbuster hopeful Dupixent.